Concert Pharmaceuticals, Inc. (CNCE): Roger D Tung , CEO of Concert Pharmaceuticals, Inc. purchased 19,610 shares on May 11, 2016. The Insider buying transaction was reported by the company on May 12, 2016 to the Securities and Exchange Commission. The shares were purchased at $10.55 per share for a total value of $206,885.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Dec 17, 2015, Richard Aldrich (director) sold 20,000 shares at $19.76 per share price.On Dec 15, 2015, Pauline Mcgowan (VP, Finance) sold 498 shares at $20.07 per share price.Also, On Nov 10, 2015, Ronald W Barrett (director) sold 17,699 shares at $22.33 per share price.On Nov 3, 2015, Nancy Stuart (Chief Operating Officer) sold 23,216 shares at $24.29 per share price.
Shares of Concert Pharmaceuticals Inc (CNCE) ended Tuesday, May 10, 2016 session in red amid volatile trading. The shares closed down -0.08 points or -0.74% at $10.67 with 2,84,387 shares getting traded. Post opening the session at $10.84, the shares hit an intraday low of $10.3 and an intraday high of $11 and the price vacillated in this range throughout the day. The company has a market cap of $237 M and the number of outstanding shares has been calculated to be 2,22,16,718 shares. The 52-week high of Concert Pharmaceuticals Inc is $25.04 and the 52-week low is $10.5.
Concert Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company applying its DCE Platform to create novel small molecule drugs. The Company’s approach starts with approved drugs advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety tolerability and efficacy. It has a pipeline of wholly owned and collaboration programs. The Company has a number of clinical candidates under development such as CTP-656 which is a product candidate for the treatment of cystic fibrosis; AVP-786 which is being investigated for treatment of neurologic and psychiatric disorders including Alzheimers agitation; CTP-730 which is a product candidate for the treatment of inflammatory diseases and JZP-386 which is a product candidate for the treatment of narcolepsy.